Breelyn Wilky, MD, discusses what key molecular insights in GIST management community oncologists should prioritize today.

Imatinib also has limited activity against blast-phase CML and relapsed Ph-chromosome–positive ALL, conditions resistant to standard chemotherapy and even to allogeneic stem-cell transplantation.

Learn about side effects, uses, cost, and more for imatinib oral tablets. This is a generic drug that treats certain types of cancer in adults and some children.

Among patients with newly diagnosed chronic-phase CML who are receiving imatinib, the long-term outcome is more favorable for those in whom a complete cytogenetic response is achieved at 12 months ...

Imatinib has now been used by more than 100,000 patients worldwide, totaling more than 200,000 patient-years of exposure, she noted. Also, the CML patient population tends to be elderly, ...

The enduring impact that imatinib (Gleevec, Novartis Pharmaceuticals) has made on the treatment of chronic myelogenous leukemia (CML), as well as on the whole field of oncology, has been ...

Imatinib interruption should not be considered for patients with advanced gastrointestinal stromal tumor who do not have progressive disease, according to results of a randomized phase 3 trial ...

Imatinib remains the first-line standard for advanced GIST with imatinib-sensitive mutations. Whether treatment interruption affects resistance to imatinib or survival remains unclear, Blay and ...

Extended imatinib maintenance was associated with substantially more adverse events (all grades), including muscle spasms (51% vs 22%), diarrhea (44% vs 23%), asthenia ...

Once imatinib commenced, the median BCR-ABL/BCR% levels in these patients were not significantly different to those on first-line imatinib for the equivalent number of months.